Screener
Viridian Therapeutics, Inc. VRDN Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| License revenue | $233 | — | $239 | — |
| Collaboration revenue - related parties | 51 | 75 | 186 | 147 |
| Total revenues | 284 | 75 | 425 | 147 |
| Operating expenses: | ||||
| Research and development (1) | 71,577 | 86,626 | 149,208 | 163,461 |
| Selling, general and administrative | 54,975 | 20,216 | 93,654 | 37,319 |
| Total operating expenses | 126,552 | 106,842 | 242,862 | 200,780 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s total revenue?
- Viridian Therapeutics, Inc. (VRDN) reported total revenue of $284K in Q2 2026.
- How has Viridian Therapeutics, Inc.'s total revenue changed year-over-year?
- Viridian Therapeutics, Inc.'s total revenue increased by 278.7% year-over-year, from $75K to $284K.
- What is the long-term trend for Viridian Therapeutics, Inc.'s total revenue?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s total revenue has grown at a 121.1% compound annual growth rate (CAGR), from $2.96M to $70.85M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Viridian Therapeutics, Inc.'s total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude